Launching of Interferon beta-1 a Clausen

Interferon beta-1a Clausen is a human recombinant protein obtained by genetical engineering processes, formulated by Laboratorios Clausen S.A.

This molecule is a glycoprotein identical to the endogenous one, produced in mammalian cells (CHO) that accomplishes the strictest analysis of biological activity and purity.

Interferon beta-1a Clausen not only diminishes the rate of relapses, but also delays the appearance of new lesions diagnosed by MRI. This is the reason why Interferon beta-1a Clausen is indicated for the treatment of relapsing-remitting Multiple Sclerosis.

Interferon beta-1a Clausen, is supplied in boxes with 3 and 12 prefilled syringes with 6 and 12 MIU.